SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Lilly Reports One-Year Psoriatic Arthritis Results for Taltz-Zepbound Combination

Eli Lilly reported 52-week Phase 3b results for its Taltz and Zepbound combination, with sustained improvements in psoriatic arthritis.

LLY

Related stories